A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma
A clinical study of safety and efficacy of treatment with Nivolumab and Bendamustine (NB) in patients with relapsed/refractory Hodgkin's lymphoma.
Hodgkin's Lymphoma
DRUG: Nivolumab|DRUG: Bendamustine Hydrochloride
Overall Response Rate (ORR) of Nivolumab in combination with Bendamustine Hydrochloride in patients with Hodgkin's lymphoma, Overall response rate (ORR), defined as proportion of patients with complete response (CR) or partial response (PR) in measurable lesions as defined by LYRIC criteria and duration of response., up to 3 months
Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03, Toxicity parameters based on NCI CTCAE 4.03 grades: hematological toxicity (CBC), hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), fatigue (attending physician assessment), rash (attending physician assessment), colitis (attending physician assessment), pneumonitis (attending physician assessment), autoimmune disorders (level of hormones, presence of autoimmune antibodies, attending physician assessment)., up to 12 months|Duration of Response (DOR), Duration of response will be measured from the time of initial response to nivolumab till documented disease progression, death or last evaluation of tumor status., up to 12 months|Time to Progression (TTP), up to 12 months|Progression-Free Survival (PFS), up to 12 months|Overall Survival (OS), up to 12 months
A clinical study of safety and efficacy of treatment with Nivolumab and Bendamustine (NB) in patients with relapsed/refractory Hodgkin's lymphoma.